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A
s a rule, genes and chromosomes come in pairs. Sex 
chromosomes are an exception to this rule. Males 
of many species have only one X chromosome, 
a male-speciﬁc Y chromosome, and a set of autosomes 
(AA). Individuals with two X chromosomes and a set of 
autosomes (XX;AA) are female. Sex chromosomes were 
ﬁrst noticed for this distinct unpaired morphology and are 
now known to have substantially different gene content 
[1]. These unusual cases have attracted a great deal of 
attention over the years, not only because of the role they 
often play in sex determination, but also as windows into 
more basic features of genes and gene networks. One such 
feature is the relationship between gene function and dose. 
Sex chromosomes allow us to question the importance 
of having a pair of each gene. With current knowledge of 
gene regulation, one can make an argument that gene dose 
should not matter. In textbooks and manuscripts, one often 
ﬁnds ﬁgures showing the relationship between genes in 
a pathway or network, replete with elegant feed-back and 
feed-forward regulatory interactions, parallel pathways, etc. 
At the transcript level, it seems logical that any inherent 
2-fold quantitative difference due to gene dose should be 
dwarfed, or even nulliﬁed, by the high-magnitude changes 
resulting from transcriptional regulation by proteins that are 
arrayed at enhancers or silencers. Basic textbook knowledge 
of genetics also suggests that dose is not very important. 
Having a single copy of most genes is not deleterious—there 
are few dominant alleles due to haploinsufﬁciency. These 
observations suggest that genes come in pairs to facilitate 
reproduction, and perhaps to provide a backup in case 
of spontaneous mutations occurring during the course of 
somatic development. It seems likely that the dose of most 
genes is unimportant because of robustness in gene networks, 
which buffers against noise and mutation [2].
Gene regulatory robustness probably makes cells and 
organisms insensitive to small differences in the dose 
of components, because such small deviations are also 
characteristic of more garden-variety noise. However, 
robustness has limits. Whereas the dose of individual 
genes does not appear to be very important, altering the 
doses of many genes is clearly detrimental. Chromosomal 
rearrangements are associated with many cancers. In some 
cases, these rearrangements break individual genes, but often 
there is a duplication or loss resulting in a change in copy 
number [3]. Monosomy (one rather than two chromosomes) 
or trisomy (three rather than two chromosomes) occur 
as a result of errors in meiosis and are highly deleterious 
during development of the resulting zygote [4]. With the 
exception of trisomy 21 and the sex chromosomes, altered 
chromosome dose is generally incompatible with human life. 
More recently, gene dose polymorphisms have been found 
to be relatively common in humans [5]. These copy number 
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Figure 1. Network Cartoon
(A) In this simple diagram, genes (circles) and regulatory connections 
(lines) are shown.
(B) Reducing the dose of one gene (red exclamation point) perturbs the 
immediately connected genes (rose), but does not collapse the network.
(C) Reducing the dose of two genes result in the loss of one part of the 
network (red slash). PLoS Biology  |  www.plosbiology.org PLoS Biology  |  www.plosbiology.org 2779
variations are the subject of a great deal of recent work, and 
may well be important factors in disease. In one of the ﬁrst 
modern genomics papers, Drosophila researchers tiled the 
genome and showed that the viability of ﬂies depends mostly 
on how much of the genome is present in one or three copies 
and not on the dose of individual genes [6]. Altering dose 
results in a mutant phenotype has an additive effect of small 
changes in the genome. 
To illustrate this point, take a small network (Figure 1A) 
where each node (a gene) has the same strength (dose). 
Quantitative disruptions at a single particular network node 
(a gene) might propagate through edges (gene activity) to 
adjacent nodes, but the structure of the network recovers with 
very little effect on the overall network structure (phenotype), 
as seen in Figure 1B. This is essentially the classic molecular 
biology model, where gene regulation restores proper 
network architecture in the face of small dose differences 
or signiﬁcant environmental (e.g., heat shock) or biological 
(e.g., insulin) cues. Such networks are resistant to random 
suboptimization, but they are susceptible to disruption 
under concerted attack, for example, by geneticists trying to 
decipher a pathway. If the dose of enough genes is altered, 
as probably occurs in the case of something on the scale 
of monosomy, then the random disruption affects near 
neighbors by chance (Figure 1C). Gene expression levels 
are the result of the integration of multiple inputs that are 
quasi-redundant, but if enough of those inputs are weakened 
by a dose change, then there is a tipping point, the defect is 
propagated, and the network fails to recover. It is this network 
collapse, not the dose of individual genes, that results in a 
mutant phenotype. 
Sex chromosomes are normally monosomic in the 
heterogametic sex (in XY systems where males have a single 
X, and in ZW systems where females have a single Z). This 
wild-type alteration is therefore a very powerful model for 
understanding how networks respond to gene dose—by 
showing us how the organism compensates for dose 
differences, how the network responds when compensation 
is absent, and how compensation evolves. The manuscript 
in this issue of PLoS Biology from Turner and colleagues 
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Figure 2. Balancing Expression
(A) With X inactivation alone, female and male gene expression is equilibrated, but X and autosome (AA) expression in both males (blue) and females 
(red) is not.
(B) X inactivation along with increased expression from the active X chromosome balances between the sexes and between X and autosome.PLoS Biology  |  www.plosbiology.org PLoS Biology  |  www.plosbiology.org 2780
[7] examines X chromosome dosage compensation in 
mammals. 
In mammalian females, one of the X chromosomes 
is condensed into largely inactive heterochromatin [8]. 
The idea is that both females and males are functionally 
monosomic for the X, and thus dose is compensated 
among the sexes (Figure 2A). This is an odd mechanism. 
In the science ﬁction story “Harrison Bergeron,” equality is 
mandated by law, such that particularly talented dancers are 
required to wear weights to disrupt their performances, and 
intellectually astute individuals have implants that periodically 
disrupt brain function [9]. Similarly, X inactivation achieves 
dosage compensation by giving females the same problems as 
males [10–12]. Unless the gene content of X chromosomes 
has become especially dosage tolerant (which would be 
quite interesting), then dosage compensation between the 
mammalian sexes would be expected to result in the same 
type of network collapse that might be expected due to 
monosomy for a major autosome. Simply put, X inactivation 
is a dosage-disrupting mechanism for females, not a dosage-
compensation mechanism. What is bad for the gander is also 
bad for the goose.
It seems likely that X inactivation is not the whole dosage-
compensation story in mammals. Work by Turner and 
colleagues [7] as well as by others [13,14] might necessitate 
the rewriting of some textbooks. These global expression-
proﬁling studies show that X chromosomes are expressed 
in balance with autosomes in both females and males. This 
leads to the idea that the single X in males and that the 
single active X in females is over-expressed relative to a single 
autosome (X times two equals A plus A). This is an attractive 
idea, because it results in X/AA dosage compensation in both 
females and males (Figure 2B). X inactivation might be best 
seen as a response of females to the overexpression of the X 
chromosome, an overexpression that males require because 
they have just one X chromosome. 
While this is a thematically pleasing idea that equilibrates 
expression between and within the sexes, the model 
represents a major paradigm shift, hinging on array analysis 
where overall X chromosome expression is compared to 
overall autosome expression. These data indicate that single 
active X chromosome expression rates (or more accurately, 
steady-state levels) are the same as those of two autosomes. 
While the datasets are quite large and in good agreement, the 
fold-changes are inherently modest. There is some autosomal 
dosage compensation in response to gene dose (buffering 
or network robustness), so X chromosome–speciﬁc dosage 
compensation results in much less than a 2-fold difference in 
expression [12,15]. There is also a counter example, where 
expression proﬁling indicates that sex chromosome dose in 
birds is poorly compensated [16]. At least some functions in 
bacterial chemotaxis are resistant to quantitative variation in 
component abundance [17]. Perhaps birds have particularly 
robust gene networks. Clearly, there is much room and 
demand for further work. 
Time-course analysis is a powerful gene-proﬁling tool, 
because having a vector in addition to a fold-change greatly 
increases conﬁdence in small magnitude changes. Lin et 
al. [7] took advantage of the ability of male and female 
mouse embryonic stem cells to differentiate in culture to 
generate a time-course for dosage compensation. The shift 
in X chromosome expression relative to autosomes during 
the differentiation of male and female mouse embryonic 
stem cells is very convincing. This strengthens the case 
for increased expression of X chromosomes and shows 
how X chromosome dosage compensation is achieved as 
development proceeds. It is known that X chromosome 
inactivation occurs during early embryogenesis [8]. As 
would be expected under either the old X-inactivation–only 
or the new increased–X expression models of dosage 
compensation, there is higher X chromosome expression 
in female cells before X inactivation than in male cells. It 
is interesting that the expression of X chromosome genes 
is higher than autosomal expression in females, suggesting 
that X chromosomes are inherently hyperactive (Figure 
3A). This in turn suggests that X inactivation is a mechanism 
for preventing functional tetrasomy in females. During the 
ﬁrst week of development, X chromosome expression in 
females decreases toward balance with the autosomes, as a 
consequence of X inactivation (Figure 3B). The situation in 
males is something of a mirror image. Expression from the 
single X chromosome in male cells is lower than expression 
from the paired autosomes, but gradually increases until 
balance with the autosomes occurs (Figure 3). This suggests 
that X chromosome expression is ramping upward during 
early male development in order to come into balance with 
autosomal expression. Thus, at face value it appears that there 
are active regulatory mechanisms in both females and males. 
While perhaps less likely, it is also possible that all the 
regulation occurs in females. It should be noted that the 
baseline expression of the single X in male embryonic 
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Figure 3. Dosage Compensation in Development, with Regulation 
in Both Sexes
(A) Initially, X and AA expression are out of balance in both males and 
females.
(B) The combination of increased X chromosome expression and X 
inactivation in females balances expression later in development.PLoS Biology  |  www.plosbiology.org PLoS Biology  |  www.plosbiology.org 2781
stem cells is already expressed more than an autosome 
is before differentiation. This may be due to an inherent 
hyperexpression from the X chromosome. However, it may 
be more likely that this increased expression is the result 
of the buffering effects of networks [12]. Dose-dependent 
expression from cells with deletions on autosomes would 
provide a valuable reference for determining whether single 
X chromosomes are always overexpressed relative to single-
copy regions on autosomes. Inherent hyperexpression of 
X chromosomes in both sexes (this certainly appears to be 
true for females) and regulated X inactivation in females 
can also result in true dosage compensation. Determining 
if X chromosome hyperexpression is gradually acquired in 
males or is a constant characteristic of X chromosomes will be 
important.
There is a large body of literature on the mechanism of X 
inactivation, which involves the expression of a noncoding 
RNA (Xist) from the X inactivation center, some type of 
cis-recognition of the chromosome to inactivate, chromatin 
modiﬁcation, and condensation [8]. There is ongoing 
debate about how important entry sites for inactivation and 
spreading might be in this process. Entry sites and spreading 
occur in interphase cells, where chromosomes are arranged 
in characteristic territories within the spherical nucleus. 
Lin et al. [7] suggest that the gradual inactivation occurs 
in groups of genes by spreading into the X-chromosome 
territory. The idea that mosaic inactivation is dependent 
on the proximity to the Xist locus in three-dimensional 
chromosome-territory space is attractive, because spreading 
in three dimensions can explain interspersed regions on X 
chromosome that might fail to inactivate initially (imagine 
pouring sauce on spaghetti). The authors show that there is 
co-inactivation of neighboring genes on the X chromosome. 
However, there is a general correlation in gene expression 
of neighboring genes on all chromosomes, so it is not really 
clear if co-inactivation tell us much about X inactivation per 
se [18]. Understanding how inactivation at the transcript 
level is gradually acquired and how this relates to the 
previous observed changes in chromosome structure is 
important but will require the pairing of expression analysis 
with more systematic global analysis of Xist and modiﬁed 
histone localization by chromatin immunoprecipitation 
(ChIP) followed by array hybridization (ChIP-Chip) or deep 
sequencing (ChIP-Seq) [19,20]. Similarly, there is a clear 
need for high-throughput mapping techniques to provide a 
three-dimensional distance measurement between a given 
location on an X chromosome and another location on the X 
or any other chromosome [21]. 
Finally, the molecular mechanisms for increases in the 
expression of X chromosomes are wholly unknown. We just 
have questions. Do the active X chromosomes in females 
and males have a more active or less repressive chromatin 
structure? Is there something entirely novel that equilibrates 
steady-state expression of X chromosomes and autosomes? 
How much dosage compensation is needed on top of an 
inherent dose-response system that should function on 
autosomes? Studying the gradual acquisition of dosage 
compensation during early mammalian development may not 
provide all the answers, but it appears to be a good place to 
start.  
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